Asuragen
Oxford Nanopore Technologies, Bio-Techne Partner to Develop Carrier Screening Assay
The project will leverage Asuragen's long-range PCR and Oxford Nanopore's sequencing capabilities to develop a sequencing workflow for carrier screening.
Thermo Fisher Scientific Deal Expands Possibilities for Exosome Dx Business, Bio-Techne CEO Says
Premium
The deal with Thermo Fisher is for the development of Bio-Techne's second test in its Exosome Diagnostics portfolio, a multigene assay for kidney transplant rejection.
In Brief This Week: Bio-Techne, Dante Labs, Metagenomi, Applied DNA Sciences, Caris Life Sciences
News items for the week of April 5, 2021.
Bio-Techne expects the acquisition will provide it with a basis to build out its IVD presence, given Asuragen's diagnostic tests and regulatory expertise.
Bio-Techne to Acquire Molecular Diagnostics Firm Asuragen for up to $320M
Bio-Techne said Asuragen's headquarters in Austin, Texas includes a scalable 50,000-square-foot manufacturing facility and CLIA-certified laboratory.
Nov 13, 2018
Health Canada Approves Two BCR-ABL Tests
Sep 7, 2018
Jul 25, 2016
Asuragen BCR-ABL Kit Granted FDA Premarket Clearance
Jun 11, 2015